Chiara Fabbroni, MD, Fondazione IRCCS, Milan, Italy, discusses the safety profile of milademetan, an inhibitor of the interaction between p53 and murine double minute 2 homolog (MDM2). Despite data from the Phase III trial currently being unavailable, data from the Phase I (NCT01877382) and II (NCT05012397) trials suggest that the two main side effects occur as a result of treatment. Grade 3 thrombocytopenia was found in 15% of patients in the study, and suggested treatment strategies for this include a transfusion in affected patients. Nausea was identified as a common side effect, occurring in 80% of patients. This interview took place at the ESMO Sarcoma and Rare Cancers Congress 2023 in Lugano, Switzerland.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
